Kiniksa Pharmaceuticals Ltd (KNSA)
16.68
+0.35
(+2.14%)
USD |
NASDAQ |
Sep 26, 16:00
16.69
+0.01
(+0.06%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.170B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 50.81% |
| Valuation | |
| PE Ratio | 5.101 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.199 |
| Price to Book Value | 2.843 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 83.06% |
Profile
| Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |
| URL | https://www.kiniksa.com |
| Investor Relations URL | https://investors.kiniksa.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 01, 2023 (est.) |
| Last Earnings Release | Jul. 25, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. |
| URL | https://www.kiniksa.com |
| Investor Relations URL | https://investors.kiniksa.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Nov. 01, 2023 (est.) |
| Last Earnings Release | Jul. 25, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |